Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability & Pharmacokinetics of AZD4877 Administered Once Weekly in Adult Patients With Recurrent or Refractory AML, PH Negative ALL, NHL or MN

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00460460

Enrollment

Registered

2007-04-16

Start date

2007-03-31

Completion date

2007-08-31

Last updated

2011-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma

Keywords

Phase I, cancer, lymphoma, leukemia, myeloma, AML, ALL, NHL, MM

Brief summary

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.

Interventions

DRUGAZD4877

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with AML, a certain type of ALL, NHL and MM * certain types of cancer of the lymph nodes * certain types of leukemias (blood cancers) * disease has or will fail with other treatments * relatively good overall health other than your cancer

Exclusion criteria

* poor bone marrow function (not producing enough blood cells) * serious heart conditions * poor liver or kidney function

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026